RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Saved in:
| Title: | RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. |
|---|---|
| Authors: | Emde-Rajaratnam M; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Beck S; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium.; Universitätsklinikum Heidelberg, Molekularpathologisches Zentrum, Heidelberg, Germany., Benes V; Europäisches Laboratorium für Molekularbiologie, GeneCore, Heidelberg, Germany., Salwender H; Asklepios Tumorzentrum Hamburg, AK Altona and St. Georg, Hamburg, Germany., Bertsch U; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany., Scheid C; Department I of Internal Medicine, University of Cologne, Cologne, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz GmbH, Chemnitz, Germany., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hielscher T; Deutsches Krebsforschungszentrum, Abteilung für Biostatistik, Heidelberg, Germany., Raab MS; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany., Goldschmidt H; Universitätsklinikum Heidelberg, Medizinische Klinik V, Heidelberg, Germany.; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany., Jauch A; Universität Heidelberg, Institut für Humangenetik, Heidelberg, Germany., Maes K; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., De Bruyne E; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Menu E; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., De Veirman K; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Moreaux J; Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France., Vanderkerken K; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Seckinger A; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium., Hose D; Department of Hematology and Immunology, Myeloma Center Brussels & Labor für Myelomforschung, Vrije Universiteit Brussel (VUB), Jette, Belgium. |
| Source: | Frontiers in immunology [Front Immunol] 2023 Nov 15; Vol. 14, pp. 1286700. Date of Electronic Publication: 2023 Nov 15 (Print Publication: 2023). |
| Publication Type: | Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
